cfDNA Extraction from Plasma (Round 1)
EQA for quality and quantity of cfDNA extracted from plasma. There are two rounds of EQA per year which need to be purchased separately. This EQA will be distributed in March 2026.
cfDNA Extraction from Plasma (Round 2)
EQA for quality and quantity of cfDNA extracted from plasma. There are two rounds of EQA per year which need to be purchased separately. This EQA will be distributed in Sept 2026.
CYP2C19 POCT
Point-of-care molecular testing (POCT) of CYP2C19 for optimisation of antiplatelet therapy (Artificial Buccal swabs)
Prostate cancer (PARPi) [Plasma, cfDNA]
BRCA1 and BRCA2 testing in cfDNA (plasma) for Prostate Cancer in the context of PARP inhibitor prescription. This EQA is sponsored.
NGS for germline CNVs pilot
EQA for quality of NGS for CNVs >50bp (Germline DNA). For whole exome or genome sequencing. Pilot EQA Scheme.
NGS for somatic SNVs and indels – tumour with germline subtraction analysis
EQA for quality of NGS for somatic SNVs and indels <50bp (FFPE). For NGS requiring a matched normal control germline sample (single gene, panel testing, whole exome sequencing or whole genome sequencing). Pilot EQA.